LRMR trades 149.3% below Wall Street's consensus target of $8.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes LRMR achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, Larimar Therapeutics, Inc. (LRMR) has a Wall Street consensus price target of $8.50, based on estimates from 8 covering analysts. With the stock currently trading at $3.41, this represents a potential upside of +149.3%. The company has a market capitalization of $292M.
Analyst price targets range from a low of $5.00 to a high of $12.00, representing a 82% spread in expectations. The median target of $8.50 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 8 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, LRMR trades at a trailing P/E of -1.5x. Analysts expect EPS to grow +17.4% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
ACADACADIA Pharmaceuticals Inc. | $4.5B | $26.20 | $34.38 | +31.2% | Buy | 68.9x | 37 |
PRAXPraxis Precision Medicines, Inc. | $9.4B | $323.95 | $589.00 | +81.8% | Buy | — | 16 |
PTCTPTC Therapeutics, Inc. | $7.4B | $89.20 | $95.83 | +7.4% | Buy | 100.7x | 26 |
FOLDAmicus Therapeutics, Inc. | $4.5B | $14.49 | $14.50 | +0.1% | Buy | 40.6x | 24 |
RAREUltragenyx Pharmaceutical Inc. | $3.5B | $35.87 | $47.11 | +31.3% | Buy | — | 33 |
AVNSAvanos Medical, Inc. | $1.2B | $24.92 | $23.00 | -7.7% | Hold | 24.9x | 8 |
MNKDMannKind Corporation | $1.3B | $4.22 | $8.50 | +101.4% | Buy | — | 19 |
IMVTImmunovant, Inc. | $8.2B | $40.09 | $45.00 | +12.2% | Buy | — | 23 |
CRLCharles River Laboratories International, Inc. | $11.0B | $228.68 | $222.11 | -2.9% | Buy | 20.6x | 37 |
IQVIQVIA Holdings Inc. | $35.3B | $208.23 | $222.40 | +6.8% | Buy | 16.2x | 44 |
Quick answers to the most common questions about buying LRMR stock.
The consensus Wall Street price target for LRMR is $8.5, representing 149.3% upside from the current price of $3.41. With 8 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
LRMR has a consensus rating of "Buy" based on 8 Wall Street analysts. The rating breakdown is predominantly bullish, with 8 Buy/Strong Buy ratings. The consensus 12-month price target of $8.5 implies 149.3% upside from current levels.
LRMR's current price is $3.41 with a consensus target of $8.5 (149.3% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $12 for LRMR, while the most conservative target is $5. The consensus of $8.5 represents the median expectation. These targets typically reflect 12-month expectations.
LRMR is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 8 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month LRMR stock forecast based on 8 Wall Street analysts shows a consensus price target of $8.5, with estimates ranging from $5 (bear case) to $12 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on LRMR, with a "Buy" consensus rating and $8.5 price target (149.3% upside). 8 of 8 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
LRMR analyst price targets range from $5 to $12, a 82% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $8.5 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.